Treatment of CD33 positive refractory acute lymphoblastic leukemia with Mylotarg

被引：6
|
作者：
Cheung, Ka-Chun [1 ]
Wong, Lap-Gate [2 ]
Yeung, Yiu-Ming [1 ]
机构：
[1] Tuen Mun Hosp, Dept Med & Geriatr, Haematol Team, Hong Kong, Peoples R China
[2] Tuen Mun Hosp, Dept Pathol, Hong Kong, Peoples R China
来源：
LEUKEMIA & LYMPHOMA | 2008年 / 49卷 / 03期
关键词：
D O I：
10.1080/10428190701882161
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：596 / 597
页数：2
相关论文
共 50 条
  • [21] Bispecific antibody drug conjugates targeting CD7 and CD33 for the treatment of acute myeloid leukemia
    Bethell, Richard
    Eberlein, Cath
    Pollard, Victoria
    Georgiou, Theonie
    Orphanides, George
    Mooney, Lorraine
    Kendrew, Jane
    Daniels, Tiffany
    CANCER RESEARCH, 2020, 80 (16)
  • [22] CD33, But Not Early T-Cell Precursor Leukemia, Is an Adverse Risk Factor in Adult Acute T-Lymphoblastic Leukemia
    Bahmanyar, Mohaminad
    Guo, Robert
    Atenafu, Eshetu
    Chang, Hong
    MODERN PATHOLOGY, 2015, 28 : 337A - 337A
  • [23] CD33, But Not Early T-Cell Precursor Leukemia, Is an Adverse Risk Factor in Adult Acute T-Lymphoblastic Leukemia
    Bahmanyar, Mohammad
    Guo, Robert
    Atenafu, Eshetzi
    Chang, Hong
    LABORATORY INVESTIGATION, 2015, 95 : 337A - 337A
  • [24] Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia
    Paul, Shilpa
    Rausch, Caitlin R.
    Nasnas, Patrice E.
    Kantarjian, Hagop
    Jabbour, Elias J.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (03) : 166 - 175
  • [25] Cytogenetically aberrant cells are present in the CD34(+)CD33(-)38(-)19(-) marrow compartment in children with acute lymphoblastic leukemia
    Quijano, CA
    Moore, D
    Arthur, D
    Feusner, J
    Winter, SS
    Pallavicini, MG
    LEUKEMIA, 1997, 11 (09) : 1508 - 1515
  • [26] CD33 antigen expression in poor prognosis acute myelogenous leukemia (AML): Correlation with response to treatment using a combination of gemtuzumab ozogamicin (GO, Mylotarg) and intensive chemotherapy.
    Herbei, L
    Venugopal, P
    Gregory, SA
    Sivaraman, S
    Telfer, MC
    Manson, SD
    BLOOD, 2003, 102 (11) : 235B - 235B
  • [27] FLOW CYTOMETRIC ANALYSIS OF POTENTIAL ANTI-CD TREATMENT MARKERS (CD20, CD22, CD33) IN PATIENTS WITH ACUTE B-LYMPHOBLASTIC LEUKEMIA
    Janeliuniene, Migle
    Matuzeviciene, Reda
    Sinkevic, Katazina
    Kucinskiene, Zita Ausrele
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2012, 82B (06) : 397 - 398
  • [28] In vitro and in vivo expansion of CD33/HBG promoter-edited HSPCs with Mylotarg
    Georgakopoulou, Aphrodite
    Li, Chang
    Kiem, Hans-Peter
    Lieber, Andre
    MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT, 2024, 32 (04)
  • [29] DEVELOPMENT, OPTIMIZATION AND FUNCTIONAL EVALUATION OF CART CELLS AGAINST CD33 FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
    Calvino, Cristina
    Alfonso, Ana
    Inoges, Susana
    Ascension Lopez-Diaz, de Cerio
    Ceballos, Candela
    Rodriguez-Marquez, Paula
    Martin-Mallo, Angel
    Calleja-Cervantes, Maria Erendira
    San, Martin-Uriz Patxi
    Rodriguez-Diaz, Saray
    Martinez-Turrillas, Rebeca
    Viguria, Maria Cruz
    Redondo, Margarita
    Lasarte, Juan Jose
    Rifon, Jose
    Rodriguez-Otero, Paula
    Rodriguez-Madoz, Juan Roberto
    Prosper, Felipe
    HAEMATOLOGICA, 2020, 105 : 81 - 82
  • [30] Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia
    Reusch, Uwe
    Harrington, Kimberly H.
    Gudgeon, Chelsea J.
    Fucek, Ivica
    Ellwanger, Kristina
    Weichel, Michael
    Knackmuss, Stefan H. J.
    Zhukovsky, Eugene A.
    Fox, Judith A.
    Kunkel, Lori A.
    Guenot, Jeanmarie
    Walter, Roland B.
    CLINICAL CANCER RESEARCH, 2016, 22 (23) : 5829 - 5838
12345